Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

107.53 -0.42 (-0.39%)
Streaming Delayed Price Updated: 11:47 AM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
71 72 Next >
News headline image
Moderna, Pfizer's Updated COVID Shot Shows Effectiveness Against 'Eris' Variant In Early Human, Preclinical Studies ↗
Moderna Inc (NASDAQ: MRNA) announced that preliminary clinical trial data confirm its updated COVID-19 vaccine for the fall 2023 vaccination season showed a significant boost in neutralizing antibodies... 
Via Benzinga
News headline image
The 3 Most Undervalued Biotech Stocks to Buy Now: August 2023 ↗
This article points you to three undervalued biotech stocks that have the potential to deliver stellar returns for patient investors. 
Via InvestorPlace
News headline image
BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer
From BioNTech SE
Via GlobeNewswire
News headline image
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership ↗
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies... 
Via Talk Markets
News headline image
What's Going On With BioNTech (BNTX) Stock? ↗
BioNTech SE - ADR (NASDAQ:BNTX) shares are trading higher by 4.66% to $106.51 Wednesday morning as the stock continues to rebound after falling on Monday. 
Via Benzinga
News headline image
What's Happening With BioNTech (BNTX) Stock? ↗
BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 3.28% to $101.73 Tuesday afternoon as the stock rebounds after falling on Monday. 
Via Benzinga
News headline image
Meet Eris, The COVID Variant Behind A Summer Resurgence In Cases: 3 Drugmakers Prep Fall Booster Shots ↗
 
Via Benzinga
News headline image
BioNTech Se (BNTX) Q2 2023 Earnings Call Transcript ↗
BNTX earnings call for the period ending June 30, 2023. 
Via The Motley Fool
News headline image
Why BioNTech Stock Was Sinking Today ↗
While the waning of the COVID pandemic is a positive development for the world, it's left the German biotech struggling. 
Via The Motley Fool
News headline image
Why Moderna Stock Sunk Today ↗
Moderna, Inc. (NASDAQ: MRNA) shares are trading lower on Monday. 
Via Benzinga
News headline image
PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
BioNTech Skids As Covid Vaccine-Maker's Sales Plummet And Miss Forecasts ↗
The company kept its sales outlook for the year, however. 
Via Investor's Business Daily
News headline image
Preview: BioNTech's Earnings ↗
 
Via Benzinga
News headline image
Analyst Ratings for BioNTech ↗
 
Via Benzinga
News headline image
Week In Review: BeiGene Options DualityBio ADC In $1.3 Billion Agreement ↗
Deals and financings, trials and approvals in the Chinese biotech/biopharma sphere. 
Via Talk Markets
News headline image
BioNTech Slips Into Quarterly Loss As Q2 Revenue Evaporates, Cuts R&D Spending For FY23 ↗
BioNTech SE (NASDAQ: BNTX) has reported Q2 revenues of €167.7 million, sharply down from €3.2 billion a year ago 
Via Benzinga
News headline image
US Stocks Eye Rebound After Big Earnings, But Inflation Data Looms: Analyst Says 3 Factors Can Take S&P 500 Past 4,800 ↗
US stocks look set for a cautious start as the week's inflation data will likely keep traders on tenterhooks. 
Via Benzinga
News headline image
BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
News headline image
Pfizer, Moderna Try To Squeeze Blood From A Stone. Why It Probably Won't Work. ↗
The company hopes to launch an updated Covid booster shot this fall. But there are several complications. 
Via Investor's Business Daily
News headline image
Expert Ratings for BioNTech ↗
 
Via Benzinga
News headline image
Price Over Earnings Overview: BioNTech ↗
 
Via Benzinga
News headline image
BioNTech Completes Acquisition of InstaDeep
From BioNTech SE
Via GlobeNewswire
News headline image
Analyst Initiates Arcturus: Sees Attractive Growth Trajectory with Vaccine Franchise Despite Competition ↗
William Blair analyst Myles Minter has initiated coverage of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) with an Outperform rating and a fair  
Via Benzinga
News headline image
BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023
From BioNTech SE
Via GlobeNewswire
News headline image
Week In Review: Novartis In $1 Billion Deal For DTx Pharma ↗
Novartis signed a $1 billion agreement to acquire DTx Pharma, a preclinical San-Diego company developing siRNA therapies for neuroscience indications. Meanwhile, Zhuhai Biotheus formed a far-reaching... 
Via Talk Markets
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2023 ↗
 
Via Benzinga
News headline image
3 Biotech Stocks That AI is Loving in July ↗
As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential. 
Via InvestorPlace
News headline image
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now ↗
With biotech stocks offering myriad viable opportunities irrespective of broader conditions, this sector is worth a closer look. 
Via InvestorPlace
News headline image
Pfizer, European Pharma Firms Collaborate With European Commission For Future Health Emergency Preparedness ↗
The European Commission has reportedly made arrangements with Pfizer Inc (NYSE: PFE) and various European pharmaceutical companies to secure the capacity to produce up to 325 million vaccines annually... 
Via Benzinga
News headline image
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
From BioNTech SE
Via GlobeNewswire
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.